LBPMedicine(SH:688393) Ge Long Hui A P P·2026-01-30 08:12Core Viewpoint - Anbiping (688393.SH) is expected to report significant losses in 2025, with net profit attributable to shareholders projected to be between -52 million to -42 million yuan, marking a substantial decline compared to the previous year [1][2] Group 1: Financial Performance - The company anticipates a net profit loss of -52 million to -42 million yuan for 2025, a decrease of 73.29 million to 63.29 million yuan year-on-year, representing a decline of 344.23% to 297.26% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between -72 million to -62 million yuan, down by 86.25 million to 76.25 million yuan compared to the previous year, indicating a decrease of 605.13% to 534.97% [1] Group 2: Revenue and Business Impact - The company's operating revenue has declined year-on-year, primarily due to the implementation of national centralized procurement policies, which significantly reduced the selling price of HPV products, leading to a revenue decrease of approximately 46.5 million yuan [2] - The gross profit margin for the HPV product line has also been under pressure, with gross profit decreasing by about 46 million yuan year-on-year [2] - The company is actively optimizing its business structure by focusing on core business revenue expansion and reducing the scale of agency product operations [2] Group 3: Strategic Initiatives - To adapt to market changes and build long-term competitive advantages, the company is enhancing its product research and development efforts, particularly in the fields of pathological intelligence and tumor companion diagnostics [2] - Although this strategy has led to an increase in operating costs in the current period, it is expected to lay a solid foundation for the company's sustainable development in the future [2]